News Conference News ESC 2020 LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease Caitlin E. Cox August 31, 2020
News Daily News High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention Michael O'Riordan August 11, 2020
News Daily News COVID-19 Clots Spur Both Arterial, Venous Events in Hospitalized Patients Caitlin E. Cox July 24, 2020
News Daily News THALES: Ticagrelor Plus Aspirin Cuts Repeat Events After Stroke, TIA Todd Neale July 16, 2020
News Daily News ‘Relatively Low’ Stroke Incidence in COVID-19, but More Are Cryptogenic Yael L. Maxwell May 25, 2020
News Features Stroke ‘Surge’ in the Young Fuels Debate Over COVID-19’s Culpability Todd Neale May 08, 2020
News Daily News Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES Michael O'Riordan May 04, 2020
News Daily News New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths Todd Neale April 10, 2020
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News ISC 2020 Industry Payments to Vascular Neurologists Jump in the Thrombectomy Era Todd Neale February 29, 2020
News Conference News ISC 2020 Optimal Time to Start Anticoagulation After Stroke Remains Unclear Todd Neale February 27, 2020
News Conference News ISC 2020 SKIP Questions Need for IV Thrombolysis Before Stroke Thrombectomy Todd Neale February 25, 2020
News Daily News Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results Michael O'Riordan January 27, 2020
News Daily News Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes Michael O'Riordan January 14, 2020
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Daily News Recurrent Events Common Among Young Patients With CAD Michael O'Riordan October 11, 2019
News Conference News ESC 2019 Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS Michael O'Riordan September 01, 2019
News Daily News Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES Michael O'Riordan August 26, 2019